Specific mechanism found to control transition from acute to chronic pain
A new study is the first to identify N-acylethanolamine acid amidase as a new drug target to treat different forms of chronic pain.
List view / Grid view
A new study is the first to identify N-acylethanolamine acid amidase as a new drug target to treat different forms of chronic pain.
27 October 2021 | By Takara Bio
Watch this free one-hour session to discover how refined cell atlases can provide comprehensive roadmaps for health and disease.
German, Norwegian and British scientists have identified molecular targets for therapies that could prevent breast cancer recurrence.
In an exclusive with Drug Target Review, researchers at the University at Buffalo explain how they developed a novel peptide that could be a future treatment for chronic inflammatory pain.
This whitepaper overviews phenotypic and functional characterisation of CAR-T cells with advanced flow cytometry and live-cell analysis.
The La Jolla Institute for Immunology and Brigham and Women's Hospital will collaborate to develop a pan-coronavirus vaccine.
A new method, called synapse for T-cell activation (synTac), can attack HIV-infected T cells and may be a new cure for HIV and other diseases.
Activating the protein channel TRPML1 induced selective melanoma cell death while sparing normal cells, suggesting a potential pathway for new cancer therapies.
Scientists have created a nanofibre-based sheet to control and direct the migration of cells, possibly leading to brain tumour therapies.
Washington University will receive $7.5 million from the NIH to study senescent cells for treatments against age-related diseases.
In a new study, a calorie-restricted diet significantly reduced tumour growth in mouse models, suggesting new possibilities for cancer therapies.
The antimicrobial hygromycin A was shown to clear Lyme disease in mice, representing a promising therapeutic against the disease.
Scientists have developed a novel technique for the targeted clearance of senescent cells to improve treatments for ageing and other conditions.
Mammalian target of rapamycin complex 2 (mTORC2) was found to prevent brain damage in mice infected with herpes simplex virus 1 (HSV-1).
Medicenna's IL-2 super-agonist, MDNA11, successfully induced antitumour cells in animal models, a pre-clinical study has revealed.